GlassScriptPhysician profile
Oliver Jeffery
NPI 1083929160
$6,122.11
in general payments reported to CMS, 2019-2025
36 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.05 · 2020: $72.77 · 2021: $563 · 2022: $1,652 · 2023: $1,212 · 2024: $1,380 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,734 · Education: $30.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,734.47 |
| Education | $30.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,254.98 | 2021-2025 | |
| Ucb, INC. | $981.09 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Dixi Medical USA Corp | $832.86 | 2022 | |
| Sk Life Science, INC. | $429.35 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $407.03 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $283.98 | 2022-2025 | |
| Pfizer INC. | $260.73 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $247.32 | 2021-2022 | |
| Emd Serono, INC. | $171.39 | 2019-2023 | Mavenclad |
| Mdd US Operations, LLC | $164.95 | 2022-2024 | Gocovri, Gocovri, Apokyn |
| Microvention, INC. | $149.77 | 2024 | Eric Retrieval Device, Chaperon Guiding Catheter, Azur Cx Detachable |
| Amgen INC. | $104.71 | 2022-2025 | Uplizna |
| Greenwich Biosciences, INC. | $104.15 | 2020-2021 | |
| Catalyst Pharmaceuticals, INC. | $79.67 | 2023-2025 | Fycompa |
| Axsome Therapeutics, INC. | $68.90 | 2025 | Symbravo, Sunosi |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $58.52 | 2022 | |
| Neuropace, INC. | $54.56 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $49.69 | 2025 | Purified Cortrophin Gel |
| Neurelis, INC. | $39.46 | 2022 | |
| Acadia Pharmaceuticals INC | $36.20 | 2021 | |
| Allergan, INC. | $35.37 | 2022 | |
| Biogen, INC. | $32.80 | 2019-2023 | Spinraza |
| Sunovion Pharmaceuticals INC. | $32.14 | 2021-2022 | |
| Tanabe Pharma America, INC. | $30.07 | 2021 | |
| Neurocrine Biosciences, INC. | $26.97 | 2021-2023 | |
| Medtronic, INC. | $21.54 | 2025 | Percept PC Brainsense |
| Arbor Pharmaceuticals, INC. | $20.09 | 2021 | |
| Boston Scientific Corporation | $18.54 | 2022 | |
| Impel Pharmaceuticals INC. | $18.39 | 2023 | Trudhesa |
| Adamas Pharmaceuticals, INC. | $17.19 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.28 | 2021 | |
| Livanova USA, INC. | $15.58 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Genentech USA, INC. | $15.51 | 2020 | |
| Scilex Pharmaceuticals INC. | $15.30 | 2022 | |
| Amneal Pharmaceuticals LLC | $14.38 | 2024 | Rytary |
| Alexion Pharmaceuticals, INC. | $12.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oliver Jeffery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.